UAE approves use of drug to combat 'silent killer' high cholesterol
The UAE has approved the use of Lipfendra, a daily cholesterol-lowering pill developed by Merck, to combat high cholesterol. The drug, which was recently authorized by the FDA, is intended to be used alongside diet and exercise to reduce heart disease risks.
Why it matters
The introduction of new pharmaceutical treatments for high cholesterol provides a critical tool in addressing a leading global cause of heart disease and stroke.
The UAE has approved the use of a daily pill to treat high cholesterol, a silent killer putting millions at heightened risk of heart disease and strokes around the world. Lipfendra, developed by US pharmaceutical company Merck, was found to significantly reduce levels of low-density lipoprotein cholesterol in clinical trials. It was authorised by the US Food and Drug Administration last month, with the Emirates becoming only the second country in the world to give it the green light. The Emirates Drug Establishment said the drug would be permitted to be used by adult patients as part of a treatment plan determined by a healthcare professional. Its cost was not disclosed. The EDE said the oral medication, taken once daily, worked to lower LDL – known as “bad cholesterol” – alongside a balanced diet and exercise.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in